Evidence map›Paper›PMID 29249058›Full record

Observational studyBreast cancer research and treatment2018

Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.

Marilyn L Kwan, Song Yao, Cecile A Laurent, Janise M Roh, Charles P Quesenberry, Lawrence H Kushi, Joan C Lo

Abstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marilyn L KwanDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. marilyn.l.kwan@kp.org.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Janise M RohDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Charles P QuesenberryDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Joan C LoDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Kaiser Permanente · USRoswell Park Comprehensive Cancer Center · US

Funding

Prospective Study of Breast Cancer SurvivorshipR01CA105274 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2004 to 2014
$19.9M
Infrastructure for Pathways, a Prospective Study of Breast Cancer SurvivorshipU01CA195565 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSONE, CHRISTINE B., KUSHI, LAWRENCE H · 2016 to 2025
$18.8M
Lifestyle and Molecular Factors of Bone Health in Breast Cancer SurvivorsR01CA166701 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KWAN, MARILYN L, YAO, SONG · 2012 to 2015
$2.5M
National Cancer Institute R01 CA105274National Cancer Institute R01 CA166701National Cancer Institute U01 CA195565NCI NIH HHS R01 CA105274NCI NIH HHS R01 CA166701NCI NIH HHS U01 CA195565
6 · The paper itself

Abstract

purposeWe assessed bone mineral density (BMD) change with aromatase inhibitor (AI) treatment in a contemporary cohort of women with breast cancer treated in Kaiser Permanente Northern California.

methodsPercent and estimated annual percent changes in BMD at the total hip and lumbar spine were examined in 676 women receiving AI therapy who had two serial BMD reports available (at least 1 year apart) before and after AI initiation (N = 317) or during continued AI therapy (N = 359). BMD changes were examined at the total hip and lumbar spine and compared by age and clinical subgroups.

resultsWomen experienced BMD declines after AI initiation or continued therapy, with median annual percent change - 1.2% (interquartile range, IQR - 2.4 to - 0.1%) at the hip and - 1.0% (IQR - 2.3 to 0.1%) at the spine after AI initiation, and - 1.1% (IQR - 2.4 to 0.1%) at the hip and - 0.9% (IQR - 2.4 to 0.5%) at the spine during continued therapy. Higher levels of bone loss were observed among younger (< 55 years) compared with older (≥ 75 years) women at the hip (- 1.6% vs. - 0.8%) and at the spine (- 1.5% vs. - 0.5%) after AI initiation, and at the hip (- 1.4% vs. - 1.2%) and at the spine (- 2.4% vs. - 0.001%) during continued therapy.

conclusionsSmall but consistent declines in total hip and lumbar spine BMD were present in breast cancer patients following AI therapy initiation or continued AI therapy. Although the overall rates of osteoporosis were low, greater estimated levels of annual bone loss were evident among women < 55 years.

Indexed as

AgedAge FactorsAntineoplastic Agents, HormonalAromatase InhibitorsBone DensityBreast NeoplasmsCaliforniaChemotherapy, AdjuvantDiphosphonatesFemaleFollow-Up StudiesHumansMastectomyMiddle AgedOsteoporosisPostmenopauseAntineoplastic Agents, HormonalAromatase InhibitorsDiphosphonatesAromatase inhibitorBone mineral densityBreast cancerEndocrine therapyOsteoporosis

Identifiers

PMID29249058
PMCPMC6534130
OpenAlexW2771953684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.